Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM1009 in advanced solid tumors
NCT05607563Phase 1Unknown
- Sponsor
- Biotheus
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PM1009 in solid tumor (advanced stage) (5 arms), sponsored by Biotheus. Primary endpoint: Dose Limited Toxicity up to 21 days. Status: unknown.
02
Drugs
PM1009
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05607563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607563.